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Prevalence of diabetes mellitus (DM) in the Hong Kong Cardiovascular Risk
Factor Prevalence Study cohort
BMY Cheung, YB Man, KSL Lam, NMS Wat, JLF Lo, DFY Chau, CY Law, TH Lam,1 GM Leung,1 SCF Tam,2 CH Cheng,
CR Kumana, CP Lau. Department of Medicine, Department of Community Medicine,1 The University of Hong Kong;
Clinical Biochemistry Unit,2 Queen Mary Hospital, Hong Kong
Introduction: 2881 randomly chosen Hong Kong men and women participated in the Hong Kong Cardiovascular
Risk Factor Prevalence Study in 1995-6. After 6 years the subjects are recalled for follow up. Here we report the
prevalence of DM in the restudied subjects.
Method: 813 subjects (393 men, 420 women; age 51±12 yrs) were randomly chosen from the cohort and were
studied in the morning after overnight fasting. A medical history was obtained from each patient. A 2-hour oral
glucose tolerance test was performed.
Results: The prevalence of DM in 1995-6 and 2001-2 is 9.6% and 15.5% respectively (p<0.001). After adjusting
for age, the prevalence of DM has increased by 35.1% (p<0.001).
Conclusion: The prevalence of DM rises sharply with age, especially after the age of 55. The prevalence of DM in
the elderly is alarmingly high and shows a rising trend.
Prevalence of DM in percentage. The number of subjects is given in brackets.
Age <35 35-44 45-54 55-64 65-74 >74
1995-6 Male 2.0 (305) 5.8 (378) 7.5 (267) 18.6 (242) 21.7 (161) —
Female 1.4 (286) 3.2 (474) 10.9 (294) 21.2 (203) 29.3 (150) —
2001-2 Male 3.3 (30) 10.3 (97) 9.6 (114) 23.9 (67) 32.9 (70) 33.3 (15)
Female 4.3 (23) 5.2 (115) 6.0 (150) 28.4 (67) 36.2 (47) 44.4 (18)
In 2001-2, the prevalence of DM in >64 years is 32.9±5.1% in men and 38.5±6.0% in women.
CVS-01
CVS-02
Use of a filter-type distal protection device in percutaneous revascularisation of
native coronary arteries
WH Chen, PY Lee, W Ng, & CP Lau. University Department of Medicine, Queen Mary Hospital, Hong Kong, China
Introduction Distal embolization of atherosclerotic and/or thrombotic debris occurs routinely during percutaneous
coronary intervention (PCI). Prevention of this phenomenon during saphenous vein graft intervention by a distal
protection device (DPD) is associated with a reduction in major adverse cardiac events. There are few data on the
use of DPDs in native coronary arteries.
Methods The FilterWire EX is a temporary filtration DPD that utilizes a 0.014” guidewire on which is mounted an
expandable loop structure attached to a thin porous filter. The filter is made of polyurethane and rotates freely on
the end of the guidewire. The loop captures particles which are retained by trapdoor action during retrieval using the
delivery sheath. The recommended vessel size is 3.5 to 5.5 mm where the filter loop is placed. The FilterWire EX
was used in 35 patients undergoing PCI of native coronary arteries. Clinical and angiographic variables were analyzed.
Results The FilterWire EX was used in 20 left anterior descending arteries, 8 right coronary arteries, and 2 left
circumflex arteries. The indications for PCI were: stable angina (17; 48.6%), recent myocardial infarction
(MI) (8; 22.9%), stable angina (6; 35%), recent unstable angina (5; 14.3%), acute MI primary PCI (4; 11.4%), and
acute MI rescue PCI (1; 2.9%). The vessel diameter at FilterWire EX deployment was 2.89 ± 0.54 mm (range 1.71 mm
to 4.42 mm; 88.6% <3.5 mm). The wire was used to cross the lesion directly in 23 patients (65.7%), using a
conventional guidewire as “buddy wire” in 5 patients (14.3%), requiring lesion predilation in 5 patients (14.3%),
and following thrombectomy in 2 patients (5.7%). The device was successfully deployed and retrieved in all cases.
Flow impairment was noted in 8 patients (22.9%) after deployment of the device but was restored to normal after
retrieval. Reversible vasospasm occurred in 11 (31.4%) patients. There was no death, myocardial infarction, and
dissection in each of the patients.
Conclusion The use of the FilterWire EX appears to be safe in native coronary arteries even with a diameter <3.5 mm
at the site of deployment. There are no complications related to its use. Large randomized controlled trials are
needed to prove the efficacy and safety of this device.
